Combination paclitaxel (Taxol®)-cisplatin vs cyclophosphamide-cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer

International Journal of Gynecological Cancer

Volumn 7, Issue SUPPL. 1, 1997, Pages 9-13

  Hoskins, W J ^a,i   Mcguire, W P ^b   Brady, M F ^c   Kucera, P R ^d   Partridge, E E ^e   Look, K Y ^f   Clarke Pearson, D L ^g   Davidson, M ^h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f INDIANA UNIVERSITY   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WALTER REED ARMY MEDICAL CENTER   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Ovarian cancer; Paclitaxel cisplatin; Paclitaxel cyclophosphamide

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030800387     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.7.s1.5.x     Document Type: Conference Paper

References (5)

1. Blessing JA. Design, analysis and interpretation of chemotherapy trials in cancer. In: Deppe G, ed. Chemotherapy of Gynecologic Cancer, 2nd edn. New York, NY: Alan R. Liss, 1990: 63-97.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
3. McGuire WP, Hoskins WJ, Brady MF, et al. An assessment of dose intense therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-99.
4. Bookman MA, McGuire WP, Kilpatrick E, et al. Phase I Gynecologic Oncology Group (GOG) study of 3-h and 24-h paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer (OvCA). Proc Am Soc Clin Oncol 1995; 14: 275 (Abstract).
5. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.